Thrilled to share this major news from the world of pharmacotherapy the FDA just greenlit oral semaglutide 25 mg (a tablet form akin to Wegovy) as the first oral GLP-1 for obesity treatment
Activation of -Catenin Signaling in CD133-Positive Dermal Papilla Cells Drives Postnatal Hair Growth
Novos GLP-1 Ozempic was already one of the top-selling drugs of 2023, with the companys GLP-1 drugs bringing in a combined $18.4 billion in sales, nearly double 2022 sales of $9.3 billion
Novo Nordisk is actively monitoring and taking action (including but not limited to issuing cease-and-desist letters) against these entities that are engaging in the unlawful sale of compounded semaglutide, disseminating false advertising, and infringing its trademarks
The opportunity lies in companies focusing on healthier, nutrient-rich products that GLP-1 users might favor
No clinical safety data exists for Melanotan-1 use during pregnancy or lactation the FDA Scenesse prescribing information lists pregnancy as a contraindication due to insufficient evidence, not because of known teratogenic effects
